AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06387953 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Therapy
Description: After the patient has been intubated in the operating room - the Bridge device intervention will be applied to the subject's ear by a trained study team member. At the time of the pre-incision pause, Initiation of the intervention (Sham therapy) will begin and will be continued throughout the surgery. The intervention will continue for 24 hours after extubation.
Study NCT05746442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered Automated Messaging
Description: An interactive smartphone based intervention will provide weekly smoking-related assessments and personalized automated messages designed to increase motivation, self-efficacy, use of coping skills, social support and to reduce nicotine withdrawal symptoms and stress for a 26 week period.
Study NCT05746442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Participants will be provided with a 8 week supply of nicotine patches
Study NCT05746442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Participants will be provided with a 8 week supply of nicotine patches
Study NCT05746442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Advice to Quit and Smoking Cessation Self Help Materials
Description: Participants will receive self-help materials from Khmer Quit Now, a national smoking cessation campaign in Cambodia
Study NCT05746442 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice to Quit and Smoking Cessation Self Help Materials
Description: Participants will receive self-help materials from Khmer Quit Now, a national smoking cessation campaign in Cambodia
Study NCT05746442 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet Assessment
Description: Participants will be asked to complete brief weekly smartphone assessments about their diet for a 26-week period
Study NCT05716542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: Fitbit wearable device, home exercise sessions, and telehealth appointments with physical therapist.
Study NCT06269315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cleaning product exposure
Description: Exposure of a small amount of a different household cleaner, hand disinfectant, their ingredients, and control with proper dilution on forearm of donors
Study NCT05300035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human monoclonal antibody (bNAbs)
Description: 1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of bNAbs (3BNC117LS \& 10-1074LS) between Day 7 and Day 10.~2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions.~3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks.~4. ART resumption, if participant encounters at least one ART resumption criteria.
Study NCT05300035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of placebo (saline solution) between Day 7 and Day 10.~2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions.~3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks.~4. ART resumption, if participant encounters at least one ART resumption criteria.
Study NCT06312176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: IV infusion
Study NCT06312176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT06312176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion
Study NCT06312176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: IV infusion
Study NCT06312176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: oral tablet
Study NCT06312176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal doxorubicin
Description: IV infusion
Study NCT04649905 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical Treatment
Description: Surgical standard-of-care treatment for knee OCD
Study NCT04649905 — intervention group
Intervention type: PROCEDURE
Intervention: Nonoperative Treatment
Description: Nonoperative standard-of-care treatment for knee OCD
Study NCT06122168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandala
Description: verbal interview, standard health care, sheet of paper showing a mandala to be colored at will
Study NCT06122168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: verbal interview and standard health care
Study NCT06368206 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Investigational device Aktiia G2C
Description: Study subjects are asked to stay seated and relaxed while successive measurements are taken with Aktiia G2C.
Study NCT06368206 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Marketed device used as reference for blood pressure monitoring: double auscultation cuff
Description: Study subjects are asked to stay seated and relaxed while successive measurements are taken with cuff for double auscultation.
Study NCT06368206 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Marketed device used as comparative device for blood pressure and pulse rate monitoring: Aktiia Bracelet G2
Description: Study subjects are asked to stay seated and relaxed while successive measurements are taken with Aktiia Bracelet G2.
Study NCT06368206 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Marketed device used as comparative device for blood pressure and pulse rate monitoring: oscillometric upper-arm cuff
Description: Study subjects are asked to stay seated and relaxed while taking successive measurements with an oscillometric upper-arm cuff.
Study NCT06368206 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Marketed device used as comparative device for blood pressure and pulse rate monitoring: oscillometric wrist cuff
Description: Study subjects are asked to stay seated and relaxed while taking successive measurements with an oscillometric wrist cuff.
Study NCT06368206 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Marketed device used as reference for pulse rate monitoring: pulse finger oximeter
Description: Study subjects are asked to stay seated and relaxed while successive measurements are taken with pulse finger oximeter.
Study NCT06565143 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial alternating current stimulation
Description: Transcranial alternating current stimulation (tACS) is a non-invasive brain stimulation tool that alters cortical excitability and activity via application of weak alternating currents.
Study NCT06565143 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial alternating current stimulation
Description: In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (30s); no current was delivered during the 30-minute intervention.
Study NCT04977960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Canrenoate
Description: potassium canrenoate for 7 days in addition to maximal medical treatment
Study NCT04700007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: A capsaicin patch will be applied on a 3x3 cm squared area on the volar forearm. The patch will be left in place for 24h after which it will be removed.
Study NCT04700007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramin cream 1% (Restamine®) will be applied on a 3x3 cm squared predetermined area on the volar forearm for 24 hours.
Study NCT04700007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Chloride
Description: Morphine solution (0.1mg/ml, Morphine Hydrochloride) 50 μl will be applied intradermally to the center of a predetermined area on the volar forearm by a 1 ml syringe.
Study NCT04700007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic saline
Description: injections of isotonic saline (0.05 ml, 0.9%) as vehicle will be performed.
Study NCT04700007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histamine
Description: A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
Study NCT04838210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EleVATE Group Care
Description: 10-session (2 hours per session) group prenatal care model following the prenatal visit schedule recommended by ACOG. In addition to pregnancy and infant-care related content, the EleVATE GC curriculum includes behavioral health strategies that can be used to manage depression and labor pain and navigate the daily frustrations and stress of life. Groups are facilitated by an obstetric clinician.
Study NCT04838210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Prenatal Care
Description: The dominant model of prenatal care in the United States, consisting of one-on-one encounters between a patient and obstetric clinician. Patients are seen for 10-15 mins every 4 weeks until 28 weeks gestation, every 2 weeks until 37 weeks or more by provider discretion), and weekly until delivery. Visits focus on routine screening tests and prenatal care.
Study NCT06165549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light therapy
Description: The light therapy will be administered by custom-made light boxes (LED) with adjustable brightness. The light intensity will be set at 5000 Lux. The intervention will consist of daily exposure for 30 minutes in the morning. The whole intervention includes 14 days.
Study NCT06165549 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Light placebo therapy
Description: The light placebo intervention will be administered by custom-made light boxes (LED) with adjustable brightness. The light intensity will be set at less than 200 Lux. The intervention will consist of daily exposure for 30 minutes in the morning. The whole intervention includes 14 days.
Study NCT06165549 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Emotion Bias Modification Training
Description: The training aims at associating gaming pictures with negative words and pictures of healthy activities with positive words. Gaming pictures are always presented with a pair of negative words. Pictures of healthy activities are always presented with a pair of positive words. Each picture is presented with a fixed pair of words. Participants will be instructed to select one word to get the most monetary reward. Specifically, selecting a fixed word of the word-pair will be associated with a high probability (eighty percent) of getting a monetary reward and a low probability (twenty percent) of no reward, and probabilities will be reversed for the other word. Each training run will comprise 100 gaming picture trials and 100 healthy-activity picture trials, presented in a pseudo-randomized order. Participants will receive two training runs every day. The whole training includes 14 days.
Study NCT04206059 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home sleep study
Description: Unattended home sleep studies will be conducted on the night preceding sedation and on the night following sedation to assess changes in slow wave homeostasis.
Study NCT04206059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acoustic stimulation (65db) up-slope of EEG with QST
Description: Acoustic stimulation (65 db) synchronized in-phase with the up-slope of EEG slow waves
Study NCT04206059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acoustic stimulation (65db) down-slope of EEG with QST
Description: 65 dB acoustic stimulation synchronized with the down-slope of the EEG slow waves (anti-phase)
Study NCT04206059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0 db with QST
Description: sham stimulation (0 dB volume)
Study NCT04206059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: All participants will receive dexmedetomidine with sedation titrated step-wise to 2, 3 or 4 ng/ml
Study NCT04206059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathe-Squeeze Task
Description: All participants will be asked to perform the breathe-squeeze task throughout the experiment. This will allow us to determine loss and return of responsiveness.
Study NCT04763668 — intervention group
Intervention type: OTHER
Intervention: Pregnant HIV positive women on ARTs
Description: Cardiovascular disease risk in pregnant HIV positive women on ARTs
Study NCT04763668 — intervention group
Intervention type: OTHER
Intervention: Babies born to HIV positive mothers on ARTs
Description: cardiovascular disease risk in the offspring of HIV positive mothers on ARTs
Study NCT05991713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modifying Exploration
Description: Participants in this group will use a mobile phone sensor data application that uses an accelerometer, Wireless Fidelity (WiFi) and/or GPS designed for smartphone devices. This technology allows the phones to capture information automatically and passively on the participant's activity. The application will be collecting participants' data 24 hours a day, 7 days a week. Participants will be asked to make alterations to their exploration levels approximately 20 days of their participation in the study.
Study NCT06589440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-8541A
Description: SR-8541A administered orally in combination with intravenous botensilimab and balstilimab
Study NCT06595953 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gaze-Contingent Music Reward Therapy
Description: All subjects will receive CBT and will be randomized to either active or control forms of GCMRT. This involves the monitoring of a patient s eye-movements during the free-viewing of computer-displayed matrices of faces expressing various emotions in tandem with the playing of pleasant music. In the active form of the therapy, music stops when subjects view negative valence faces, whereas in the control condition, music plays continuously. Subjects undergo 12 weeks of CBT, where GCMRT is delivered in the last eight weeks of therapy.
Study NCT06595953 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Gaze-Contingent Music Reward Therapy
Description: All subjects will receive CBT and will be randomized to either active or control forms of GCMRT. This involves the monitoring of a patient s eye-movements during the free-viewing of computer-displayed matrices of faces expressing various emotions in tandem with the playing of pleasant music. In the active form of the therapy, music stops when subjects view negative valence faces, whereas in the control condition, music plays continuously. Subjects undergo 12 weeks of CBT, where GCMRT is delivered in the last eight weeks of therapy.
Study NCT06601179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU
Description: high-intensity focused ultrasound treatment of benign prostatic hyperplasia
Study NCT05081219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin (Humulin® R U-100)
Description: Participants will administer 40 IU of Humulin® U-100 insulin four times per day with an intranasal delivery device.
Study NCT05081219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Participants will be assigned to receive Empagliflozin 10 mg capsules to be taken by mouth once daily.
Study NCT05081219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aptar Pharma CPS Intranasal Delivery Device
Description: Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.
Study NCT05081219 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Aptar Pharma CPS Intranasal Delivery Device
Description: Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.
Study NCT05081219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Insulin Diluent)
Description: Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.
Study NCT05081219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Insulin Diluent)
Description: Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.
Study NCT05081219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Capsules)
Description: Participants will be assigned to receive placebo capsules (Empagliflozin 10 mg) to be taken by mouth once daily.
Study NCT05081219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Capsules)
Description: Participants will be assigned to receive placebo capsules (Empagliflozin 10 mg) to be taken by mouth once daily.
Study NCT06668922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
Study NCT05505942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LPA Sessions
Description: A study interventionist will conduct phone/video sessions and provide information regarding the acute and long-term psychological and physical benefits of increasing PA. Participants will be introduced to the concept of utilizing brief bouts of PA as a coping strategy for managing emotions and urges to drink alcohol in-the-moment. Participants will also be given information on the public health guidelines for PA (and how these translate into step counts) as well as how to determine if their PA is moderate intensity (e.g., measuring heart rate and identifying rate of perceived exertion). Study clinicians will also orient participants to the proper use of the Fitbit activity tracker and tips for self-monitoring step counts with the tracker and on the app and/or website.
Study NCT05505942 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Only
Description: Interventionists will provide participants information about the proper use of the Fitbit activity tracker and offer tips for self-monitoring step counts with the tracker and on the app and/or website.
Study NCT05875571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Patients will get IV ketorolac during IUD placement under sedation
Study NCT05875571 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will get IV placebo during IUD placement under sedation
Study NCT04757103 — intervention group
Intervention type: PROCEDURE
Intervention: Resection of the retrorectal tumor
Description: Surgical resection of the retrorectal mass
Study NCT05543811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food for special dietary use
Description: Food for special dietary use (spread) with modified ingredients' content will be included to the diet of 70 patients without significant organic pathology for 14 days receiving standard diet, modified by the inclusion of two portions of the spread, 20 grams each for breakfast and dinner
Study NCT05543811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Food for special dietary use
Description: Food for special dietary use (spread) with modified ingredients' content will be included to the diet of 70 patients without significant organic pathology for 14 days receiving standard diet, modified by the inclusion of two portions of the spread, 20 grams each for breakfast and dinner
Study NCT05273281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transabdominal plane block
Description: Peripheral nerve block
Study NCT05273281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block
Description: Peripheral nerve block
Study NCT05931107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress ball practice group (Stress ball squeezing)
Description: The stress ball is made of round, colorful, high-quality silicone. A stress ball of medium hardness and 6 cm in diameter (suitable for adult use) will be used in the research. When it is loosened, it returns to its original state. In the experimental group, the patients are required to squeeze the ball once after counting to three, inhale each time they squeeze the ball, exhale when they loosen their grip, and focus only on the ball. The experimental group has to squeeze the stress ball for 10-15 minutes every day for 4 weeks.
Study NCT05568823 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Measurement of markers of disease evolution
Study NCT06174402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate 200 mg/day
Study NCT06174402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet/ day
Study NCT06174402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Description: UDCA 13-15mg/kg/day
Study NCT05344365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone
Description: oral tablet
Study NCT04784039 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transesophageal echocardiography
Description: Patients randomized to the TEE group will be scheduled for cardioversion with prior TEE